Evaluating rezatapopt*, a first-in-class p53 reactivator, as a treatment for TP53 Y220Cmutant locally advanced and metastatic solid tumours The experts discuss: TP53 Y220C mutation and rationale for targeted therapy Study overview and practice implications, spotlighting ovarian cancer Testing strategies for early and accurate patient identification Video in this post *Rezatapopt is an investigational agent which is not approved by a regulatory agency This programme has been sponsored by PMV Pharma #MedicalEducation #Oncology Update from AACRNCIEORTC 2025: PYNNACLE Phase 2 evaluating rezatapopt in TP53 Y220Cmutant solid tumours To view or add a comment, sign in 26,264 followers
The idea behind creating BPC-157 Arginate was to address the primary limitation of the acetate version: its fragility
BPC157 Peptide Therapy BPC157 operates by promoting angiogenesis, encouraging the formation of new blood vessels , and stimulating cell migration to injured areas
For optimal results, consider a Wellness IV infusion a day before a marathon or race, before traveling, or within several days after a significant race or athletic event to aid recovery
[7] Demirta H, zer A, Yldrm AK, Dursun AD, Sezen C, Arslan M
i vi cc tn lm p th Glutathione cn c bit n nh mt "thn dc" gip lm sng da v ngn nga tnh trng nm, tn nhang